ScottCBrunMD

PubMed

• 95 citations
  A 96-Week Comparison of Lopinavir- Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy
  D. William Cameron, Barbara A. da Silva, Jose R. Arribas, Robert A. Myers, Nicholaos C. Bellos, Norbert Gilmore, Martin S. King, Barry Bernstein, Scott C. Brun, George...> ;The Journal of Infectious Diseases. 2008 Jul 15
• 524 citations
  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
  Sarah Palmer, Frank Maldarelli, Ann Wiegand, Barry Bernstein, George J. Hanna, Scott C. Brun, Dale J. Kempf, John W. Mellors, John M. Coffin, Martin S. King> ;Proceedings of the National Academy of Sciences of the United States of America. 2008 Mar 11
• 48 citations
  Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.
  Robert L. Murphy, Barbara A. da Silva, Charles B. Hicks, Joseph J. Eron, Roy M. Gulick, Melanie A. Thompson, Florence I. McMillan, Martin S. King, George J. Hanna, Sco...> ;HIV Clinical Trials. 2008 Jan 1
• 12 citations
  High-Dose Lopinavir/Ritonavir in Highly Treatment-Experienced HIV-1 Patients: Efficacy, Safety, and Predictors of Response
  Daniel Podzamczer, Martin S. King, Cheri E. Klein, Charles Flexner, Christine Katlama, Diane V. Havlir, Scott Letendre, Joseph J. Eron, Scott C. Brun, Barry Bernstein> ;HIV Clinical Trials. 2007 Jul 1
• 10 citations
  Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients.
  Yi-Lin Chiu, Cheri E. Klein, William C. Woodward, Kathryn R. King, Christian Naylor, Walid M. Awni, Scott C. Brun> ;AIDS Patient Care and Stds. 2007 Apr 26
• 278 citations
  ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia
  Frank Maldarelli, Sarah Palmer, Martin S. King, Ann Wiegand, Michael A. Polis, JoAnn M. Mican, Joseph A. Kovacs, Richard T. Davey, Diane Rock-Kress, Robin Dewar, Shuyi...> ;Plos Pathogens. 2007 Apr 6
• 118 citations
  The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and dimini...
  Cheri E. Klein, Yi-Lin Chiu, Walid M. Awni, Tong Zhu, Renee S Heuser, Thao Doan, Joerg Breitenbach, John B Morris, Scott C. Brun, George J. Hanna> ;Journal of Acquired Immune Deficiency Syndromes. 2007 Apr 1
• 17 citations
  Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
  Kit N. Simpson, Michelle P. Luo, Elinor C. G. Chumney, Martin S. King, Scott C. Brun> ;Clinical Drug Investigation. 2007 Jan 1
• 96 citations
  A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.
  Margaret A. Johnson, Joseph Gathe, Daniel Podzamczer, Jean-Michel Molina, Christian Naylor, Yi-Lin Chiu, Martin S. King, Thomas Podsadecki, George J. Hanna, Scott C. Brun> ;Journal of Acquired Immune Deficiency Syndromes. 2006 Oct 1
• 34 citations
  Pharmacokinetics of Lopinavir/Ritonavir in HIV/Hepatitis C Virus–Coinfected Subjects With Hepatic Impairment
  Joanna Z. Peng, Federico Pulido, Sonja J. Causemaker, Jianling Li, Alicia Lorenzo, Concepción Cepeda, Juan A. García Cabanillas, Barbara DaSilva, Scott C. Brun, Jose R...> ;Journal of Clinical Pharmacology. 2006 Mar 1
• 10 citations
  Substitution with Lopinavir/Ritonavir Improves Patient-Reported Outcomes Including Quality of Life in Patients Who Were Intolerant to Their Antiretroviral Therapy
  Eduardo Sprinz, J. Andrade Neto, Eduardo Bargman, Stephen L. Green, Michelle P. Luo, Jacquelyn R. Sylte, Florence I. McMillan, Kathryn R. King, Richard A. Rode, Scott ...> ;HIV Clinical Trials. 2006 Jan 1
• 23 citations
  Liver Injury and Changes in Hepatitis C Virus (HCV) RNA Load Associated with Protease Inhibitor–Based Antiretroviral Therapy for Treatment-Naive HCV-HIV–Coinfected Pat...
  Kenneth E. Sherman, Norah J. Shire, Paul Cernohous, Susan D. Rouster, Janice H. Omachi, Scott C. Brun, Barbara A. da Silva> ;Clinical Infectious Diseases. 2005 Oct 15
• 67 citations
  Relationship between Adherence and the Development of Resistance in Antiretroviral-Naive, HIV-1—Infected Patients Receiving Lopinavir/Ritonavir or Nelfinavir
  Martin S. King, Scott C. Brun, Dale J. Kempf> ;The Journal of Infectious Diseases. 2005 Jun 15
• 72 citations
  Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutati...
  Hongmei Mo, Martin S. King, Kathryn R. King, Akhteruzzaman Molla, Scott C. Brun, Dale J. Kempf> ;Journal of Virology. 2005 Mar 15
• 54 citations
  Cost-Effectiveness of Lopinavir/Ritonavir Versus Nelfinavir As the First-Line Highly Active Antiretroviral Therapy Regimen for HIV Infection
  Kit N. Simpson, Michelle P. Luo, Elinor Chumney, Eugene Sun, Scott C. Brun, Talat Ashraf> ;HIV Clinical Trials. 2004 Sep 1
• 26 citations
  Baseline HIV-1 RNA Level and CD4 Cell Count Predict Time to Loss of Virologic Response to Nelfinavir, but Not Lopinavir/Ritonavir, in Antiretroviral Therapy—Naive Pati...
  Martin S. King, Barry Bernstein, Sharon Walmsley, Renslow Sherer, Judith Feinberg, Ian Sanne, Paul Cernohous, Julio S. G. Montaner, Scott C. Brun, Eugene Sun> ;The Journal of Infectious Diseases. 2004 Jul 15
• 92 citations
  Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
  Charles B. Hicks, Martin S. King, Roy M. Gulick, A. Clinton White, Joseph J. Eron, Harold A. Kessler, Constance A. Benson, Kathryn R. King, Robert L. Murphy, Scott C. ...> ;AIDS. 2004 Mar 26
• 184 citations
  Incidence of Resistance in a Double-Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine
  Dale J. Kempf, Martin S. King, Barry Bernstein, Paul Cernohous, Eric Bauer, Jennifer M. Moseley, Kai Gu, Ann Hsu, Scott C. Brun, Eugene Sun> ;The Journal of Infectious Diseases. 2004 Jan 1
• 75 citations
  Determining the Relative Efficacy of Highly Active Antiretroviral Therapy
  Michael Louie, Christine Hogan, Michele Di Mascio, Arlene Hurley, Viviana Simon, James F. Rooney, Nancy Ruiz, Scott C. Brun, Eugene Sun, Alan S. Perelson, David D. Ho,...> ;The Journal of Infectious Diseases. 2003 Mar 15
• 132 citations
  Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretre...
  Ann Hsu, Jeffrey D. Isaacson, Scott C. Brun, Barry Bernstein, Wayne Lam, Richard Bertz, Cheryl Foit, Karen Rynkiewicz, Bruce Richards, Martin S. King, Richard A. Rode,...> ;Antimicrobial Agents and Chemotherapy. 2003 Jan 1
• 97 citations
  Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavi...
  Dale J. Kempf, Jeffrey D. Isaacson, Martin S. King, Scott C. Brun, Jacquelyn R. Sylte, Bruce Richards, Barry Bernstein, Richard A. Rode, Eugene Sun> ;Antiviral Therapy. 2002 Sep 1
• 537 citations
  Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
  Sharon Walmsley, Barry Bernstein, Martin T. King, Jose R. Arribas, Gildon N. Beall, Peter Ruane, Margaret Johnson, David W. Johnson, Richard G. Lalonde, Anthony J. Jap...> ;The New England Journal of Medicine. 2002 Jun 27
• 126 citations
  Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus Type...
  Constance A. Benson, Steven G. Deeks, Scott C. Brun, Roy M. Gulick, Joseph J. Eron, Harold A. Kessler, Robert L. Murphy, Charles B. Hicks, Martin S. King, David Wheele...> ;The Journal of Infectious Diseases. 2002 Mar 1
• 185 citations
  Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral...
  Dale J. Kempf, Jeffrey D. Isaacson, Martin S. King, Scott C. Brun, Yi Xu, Kathryn Real, Barry Bernstein, Anthony J. Japour, Eugene Sun, Richard A. Rode> ;Journal of Virology. 2001 Aug 15
• 194 citations
  ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
  Robert L. Murphy, Scott C. Brun, Charles B. Hicks, Joseph J. Eron, Roy M. Gulick, Martin S. King, A. Clinton White, Constance A. Benson, Melanie A. Thompson, Harold A....> ;AIDS. 2001 Jan 5
• Join now to see all